rs81002849
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.517-1G>A variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000059.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.517-1G>A | splice_acceptor_variant, intron_variant | Intron 6 of 26 | 5 | NM_000059.4 | ENSP00000369497.3 | |||
BRCA2 | ENST00000530893.7 | c.148-1G>A | splice_acceptor_variant, intron_variant | Intron 6 of 26 | 1 | ENSP00000499438.2 | ||||
BRCA2 | ENST00000614259.2 | n.517-1G>A | splice_acceptor_variant, intron_variant | Intron 5 of 25 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:3
- -
- -
- -
Hereditary breast ovarian cancer syndrome Pathogenic:2
- -
This sequence change affects an acceptor splice site in intron 6 of the BRCA2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with breast cancer (PMID: 22425665). ClinVar contains an entry for this variant (Variation ID: 51800). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 21735045, 30883759; Invitae). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
Canonical splice site variant demonstrated to result in exon 7 skipping, leading to a null allele in a gene for which loss-of-function is a known mechanism of disease (Menndez 2012, Fraile-Bethencourt 2019); Observed in an individual with breast cancer (Tazzite 2012); Not observed in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 745-1G>A; This variant is associated with the following publications: (PMID: 30883759, 29446198, 24606420, 23697973, 30263132, 26295337, 22425665, 21735045) -
Familial cancer of breast Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.517-1G>A intronic pathogenic mutation (also known as 745-1G>A or IVS6-1G>A) results from a G to A substitution one nucleotide before coding exon 6 of the BRCA2 gene. This mutation has been reported in an Arab individual diagnosed with breast cancer at age 33 who had no family history of cancer (Tazzite A et al. Gynecol Oncol. 2012 Jun;125(3):687-92). This mutation was shown to cause the skipping of coding exon 6 (described as exon 7) by RT-PCR analysis (Menendez M et al. Breast Cancer Res Treat. 2012 Apr;132(3):979-92). This alteration is also shown to result in the loss of a single nucleotide at the 5' end of coding exon 6 in the mRNA (Ambry internal data; Fraile-Bethencourt E et al. J Pathol, 2019 08;248:409-420). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at